Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
13/10/2026 21:27
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports Oct 13 (Reuters) - Danish drugmaker Zealand Pharma ZELA.CO and Generate Biomedicines GENB.O have struck a deal worth up to nearly $1.2 billion to develop obesity treatments using artificial intelligence, Bloomberg News reported on Tuesday.
The agreement includes $30 million upfront and $35 million in early milestone payments, Bloomberg reported, citing a document.
Zealand Pharma did not did not immediately respond to a Reuters request for comment.
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)